Shionogi/GSK HIV integrase inhibitor looks good at Phase II
This article was originally published in Scrip
Shionogi and GlaxoSmithKline have released the first clinical data for an oral HIV integrase inhibitor they are jointly developing, which suggest it may be effective in once-daily doses without an added booster.
You may also be interested in...
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.